Trial Profile
A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Clinical Trial to Assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects With Papulopustular Rosacea
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Apr 2020
Price :
$35
*
At a glance
- Drugs Azelaic acid (Primary)
- Indications Rosacea
- Focus Registrational; Therapeutic Use
- Sponsors Bayer
- 31 Jul 2015 According to Foamix media release, the US FDA has approved azalaic acid (Finacea) foam, 15% for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.
- 24 Jul 2014 Primary endpoint (Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment) has been met, according to Bayer HealthCare media release.
- 24 Jul 2014 Primary endpoint (Nominal Change From Baseline in Inflammatory Lesion (IL) Count at End of Treatment (LOCF)) has been met, according to Bayer HealthCare media release.